Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit - 03/09/11
Abstract |
PURPOSE: To determine the effect of the topical ocular hypotensive drug, isopropyl unoprostone, a docosanoid molecule with very weak prostaglandin activity, on herpes keratitis in the rabbit eye.
METHODS: For acute disease, rabbit corneas inoculated with the corticosteroid-sensitive F(MP)E strain of herpes simplex virus type 1 were treated with various combinations of 0.12% isopropyl unoprostone, latanoprost, trifluridine, benzalkonium chloride 0.02%, dexamethasone sodium phosphate, ketorolac tromethamine, or saline solution beginning 1 day after infection. Severity of keratitis was evaluated in a masked manner. For recurrent disease, rabbit corneas infected with McKrae strain herpes simplex virus type 1 were treated with unoprostone or saline solution on postinfection days 25 to 42, and the presence or absence of lesions was recorded.
RESULTS: Eyes treated with unoprostone showed significantly less severe disease than saline-treated or latanoprost-treated eyes during acute infection. Unoprostone-treated and saline-treated eyes showed no significant difference in the frequency of recurrent lesions. Eyes treated with latanoprost and/or dexamethasone, separately or in combination, showed increased severity of acute herpes simplex virus keratitis, whereas benzalkonium chloride 0.02%–treated eyes showed no significant difference, compared with saline treatment. Trifluridine resulted in rapid healing.
CONCLUSIONS: Unoprostone did not increase the severity or recurrence rate of herpes simplex virus keratitis. Unoprostone requires twice-a-day administration, compared with once-a-day for latanoprost, and unoprostone lowers intraocular pressure less than latanoprost. Nevertheless, unoprostone’s superior safety profile may make its use advantageous. Benzalkonium chloride alone did not make the keratitis worse.
Le texte complet de cet article est disponible en PDF.Plan
☆ | This study was supported in part by US Public Health Service Grants EY02672 (Dr Kaufman) and EY02377 (Dr Kaufman) from the National Eye Institute, National Institutes of Health, Bethesda, Maryland, and an unrestricted departmental grant from Research to Prevent Blindness, New York, New York. |
Vol 131 - N° 5
P. 643-646 - mai 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?